EZH2 and sarcoma: Tazemetostat is a KMT inhibitor targeting EZH2 (Italiano et al., 2018) and G9a (Soumyanarayanan and Dymock, 2016; Dockerill et al., 2020) that has been approved for the treatment of sarcomas (Italiano et al., 2018; Gounder et al., 2020) and sensitizes ovarian cells to DNA damage (Karakashev et al., 2020).